Celestone
Radiculopathy
Sheba Medical CenterUNKNOWNPhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Radiculopathy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Kenacort University of Miami | Phase 4 | BBB |
Lidocaine Sheba Medical Center | Phase 4 | BBB |
sp-102 Semnur Pharmaceuticals, Inc. | Phase 3 | BB |
Dexasone Semnur Pharmaceuticals, Inc. | Phase 4 | BB |
Marcaine Express Specialty Pharmacy | Phase 3 | BB |
View all 35 →
Same molecule, other indications
Celestone is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →